CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...